FDA issued a permit for use of the new product Tenex Health - TX1 - a system to remove damaged or necrotic tissue. This application will allow a wide range of surgical procedures and interventions - abdominal surgery, orthopedic surgery, laparoscopy, Plastic and Reconstructive Surgery.

The company currently offers products for the treatment of damaged tissue in the tendons in chronic tendon pain. INSTRUMENTS is the size of a pen and allows surgeons to supply energy in the form of ultrasonic waves through a needle that cuts and removes only the dead tissue. The whole procedure was carried out for 20 minutes under local anesthetic.

Each year in the U.S. alone, the number of operations in tendon pain is over 10 million. Extending the testimony of multiple device will increase its applicability and convenience for physicians and patients, and the quality of the manipulation.

According to Jill Foosball - Executive Director of Tenex Health, the device allows surgery at an early stage of the disease, allowing for faster, easier and more effective treatment and faster return patients to their daily activities. He said TH1 offers unique advantages - minimum invasiveness, which means speed, efficiency and safety of the procedures with minimal recovery time.

The company designs and other products for minimally invasive surgery for the treatment of soft tissue injuries when bursitis, carpal tunnel surgery syndrome and post surgical adhesions.

Medicine for the treatment of cancer based on a virus destroying tumor cells for the first time successfully passed clinical trials in advanced stage, said U.S. pharmaceutical manufacturer Amgen.

A statement from the company product has achieved the main objective of the Phase III clinical trial in patients with advanced melanoma - the most aggressive type of skin cancer. The results showed that 16% of patients who received treatment had a significant tumor poured lasting six months or more, compared with only 2% of the control group.

A spokesman for the company declined to say whether the company will apply for registration to the FDA on the basis of this study.

It contains the virus Talimogene laherparepvec, genetically modified in a way that causes him to multiply only in rapidly growing cells. The product is injected directly into the tumor, after which the virus enters the cancer cells and causes them to synthesize large amounts of granulocyte-monocyte colony stimulating factor - the hormone that stimulates the maturation of immune cells. When cancerous cells die, they release new amounts of virus and acquired therein colony stimulating factor, which boost the immune system.

The study was conducted in 400 patients, two thirds of whom received injections every two weeks. The rest of the participants received injections only granulocyte-monocyte colony stimulating factor. According to Dr. Anthony Ribas, melanoma specialist at the University of Los Angeles, the study results are positive, but it is uncertain whether sufficient authorization for use.